Targeted genotyping of circulating tumor DNA for dynamic monitoring of recurrence and screening of drug resistance genes in extranodal NK/T-cell lymphoma, nasal-type

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2000035893

Enrollment

Unknown

Registered

2020-08-19

Start date

2020-09-01

Completion date

Unknown

Last updated

2020-08-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Tumor of lymphoid hematopoietic tissue

Interventions

Case series:Nil

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. patients who had not been treated before and were confirmed as ENKTL by histopathological examination; 2. Aged 18 to 70 years; 3. Estimated survival > 6 months; 4. Ecog Physical State Score 0-2; 5. Unstained tissue (wax or unstained glass) is available; 6. Understand and voluntarily sign a written informed consent and comply with research requirements.

Exclusion criteria

Exclusion criteria: Patients who meet any of the following exclusion criteria will be excluded: 1. Previous diagnosis or treatment with ENKTL; 2. History of malignancy in the past 5 years; 3. Other malignancies known to be progressing or requiring aggressive treatment; 4. The researchers considered not suitable for the participation.

Design outcomes

Primary

Measure	Time frame
Gene mutation spectrum;	—

Countries

China

Contacts

Public ContactYu Bao-Hua

Fudan University Shanghai Cancer Center

yubh2014@163.com+86 18017317108

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026